Efficacy of gefitinib and erlotinib in non-small-cell lung carcinoma

Lung cancer is a type of cancer that often occurs after breast cancer and prostate cancer. Lung cancer is one of the main causes of mortality in men and women in the United States. Nonsmall cell carcinoma is the most common type of lung cancer, complying more than 85% of all lung cancers. The anti-cancer therapy that is currently developing is inhibiting the work of EGFR, one of which is the tyrosine kinase inhibitor that works in the intracellular. Gefitinib and Erlotinib are two epidermal growth factor receptors tyrosine kinase inhibitors) with similar mechanism and nearly the same clinical efficacy in non-small cell carcinoma. There is no data in the Regional Public Hospital Dr Soetomo that compares the efficacy of gefitinib and erlotinib so that this study aims to compare the efficacy of gefitinib and erlotinib in the Non-small cell carcinoma that treated at One-Roof Oncology Poly Regional Public Hospital Dr Soetomo Surabaya, East Indonesia referral hospital. Methods: This study is an analytical study by means of retrospective cohort design. This study involved 94 patients who met the inclusion criteria. Patients who did not complete the data as well as drug side effects that cause epidermal growth factor receptors tyrosine kinase inhibitors therapy to be changed or their doses permanently changed are not included in this study. This research was conducted at the One-Roof Oncology Poly Dr. Soetomo Surabaya, Indonesia from January 2016 to August 2018. Results: Based on the results of the chi-square test on drug response, side effects, Progression Free Survival and Overall Survival in both groups showed that the value of p> 0.05. Conclusion: The efficacy between gefitinib and erlotinib is not different in non-small cell carcinoma lung cancer patients in the Poli oncologi Satu Atap Regional Public Hospital Dr. Soetomo Hospital Surabaya.